Sarepta Therapeutics Announces Eteplirsen Demonstrates Stability on Pulmonary Function Tests through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

Read more: http://www.nasdaq.com/press-release/sarepta-therapeutics-announces-...

Views: 364

Reply to This

Replies to This Discussion

Eteplirsin is clearly successful. All dmd parents should review comments at Fridays congressional hearing (from jenn, Christine, and mindy). Dmd experts testified as to the safety and effectiveness of eteplirsin.
Dmd parents and researchers speak about eteplirsin at congressional hearing.


http://m.youtube.com/watch?v=DTZizFZOtQY&feature=youtu.be&d...

Reply to Discussion

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service